李建龙;王健;史占军;

• 1:南方医科大学南方医院关节与骨病外科

摘要(Abstract)：

树突状细胞(dendritic cell, DC)是体内最重要、功能最强大的专职抗原递呈细胞(APC),且是机体内唯一能激活初始T淋巴细胞的APC,可有效触发诱导细胞毒性T细胞免疫应答。DC参与抗原摄取、加工处理和递呈。以DC为主特别DC疫苗的抗肿瘤疗法已取得令人鼓舞的进展。然而,DC疫苗目前还存在一定的局限性。骨肉瘤抗原异常表达、MHC-I分子下调以及肿瘤微环境中高浓度免疫抑制因子的存在等原因使得骨肉瘤发生免疫逃逸,限制了DC疫苗的应用。本文现就以DC疫苗及骨肉瘤相关免疫治疗基础进行综述。

关键词(KeyWords)： 树突状细胞;骨肉瘤;免疫治疗;免疫逃逸

Abstract:

Keywords:

基金项目(Foundation): 南方医科大学南方医院院长基金项目(编号:2017B030)

作者(Author): 李建龙;王健;史占军;

Email:

DOI:

参考文献(References)：

• [1]Isakoff MS,Bielack SS,Meltzer P,et al.Osteosarcoma:current treatment and a collaborative pathway to success[J].J Clin Oncology,2015,33(27):3029-3035.
• [2]Sabado RL,Bhardwaj N.Dendritic cell immunotherapy[J].Annals New York Academy Sci,2013,1284:31-45.
• [3]Banday AH,Jeelani S,Hruby VJ.Cancer vaccine adjuvants--recent clinical progress and future perspectives[J].Immunopharmacol Immunotoxicol,2015,37(1):1-11.
• [4]Guilliams M,Ginhoux F,Jakubzick C,et al.Dendritic cells,monocytes and macrophages:a unified nomenclature based on ontogeny[J].Nat Rev Immunol,2014,14:571.
• [5]Schott M.Immunesurveillance by dendritic cells:potential implication for immunotherapy of endocrine cancers[J].Endocrine Related Cancer,2006,13(3):779-795.
• [6]Fecci PE,Heimberger AB,Sampson JH.Immunotherapy for primary brain tumors:no longer a matter of privilege[J].Clin Res,2014,20(22):5620-5629.
• [7]Krishnadas DK,Shusterman S,Bai F,et al.A phase i trial combining decitabine/dendritic cell vaccine targeting mage-a1,mage-a3and ny-eso-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma[J].Cancer Immunol Immunother,2015,64(10):1251-1260.
• [8]Garg AD,Coulie PG,Van den Eynde BJ,et al.Integrating nextgeneration dendritic cell vaccines into the current cancer immunotherapy landscape[J].Trends Immunol,2017,38(8):577-593.
• [9]Pitt JM,Andre F,Amigorena S,et al.Dendritic cell-derived exosomes for cancer therapy[J].J Clin Investigation,2016,126(4):1224-1232.
• [10]Kitano M,Yamazaki C,Takumi A,et al.Imaging of the cross-presenting dendritic cell subsets in the skin-draining lymph node[J].Proc Nati Acad Sci,2016,113(4):1044-1049.
• [11]Reise Sousa C.Dendritic cells in a mature age[J].Nature Rev Immunology,2006,6(6):476-483.
• [12]Garrido F,Aptsiauri N,Doorduijn EM,et al.The urgent need to recover mhc class i in cancers for effective immunotherapy[J].Curr Opin Immunol,2016,39(1):44-51.
• [13]Yan GN,Lv YF,Guo QN.Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets[J].Cancer Lett,2016,370(2):268-274.
• [14]Jain A,Pasare C.Innate control of adaptive immunity:beyond the three-signal paradigm[J].J Immunol,2017,198(10):3791-3800.
• [15]Dong Q,Ma X.B7-h4 expression is associated with tumor progression and prognosis in patients with osteosarcoma[J].Bio Med Res Int,2015,2015(6)1-10.
• [16]Alfranca A,Martinez-Cruzado L,Tornin J,et al.Bone microenvironment signals in osteosarcoma development[J].Cellular Molecular Life Sci,2015,72(16):3097-3113.
• [17]Zhou SL,Zhou ZJ,Hu ZQ,et al.Tumor-associated neutrophils recruit macrophages and t-regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib[J].Gastroenterol,2016,150(7):1646-1658 e1617.
• [18]Wang X,Liang X,Liang H,et al.Senp1/hif-1alpha feedback loop modulates hypoxia-induced cell proliferation,invasion,and emt in human osteosarcoma cells[J].J Cell Biochem,2018,119(2):1819-1826.
• [19]Sousa S,Maatta J.The role of tumour-associated macrophages in bone metastasis[J].J Bone Oncol,2016,5(3):135-138.
• [20]Prendergast GC,Malachowski WJ,Mondal A,et al.Chapter fourindoleamine 2,3-dioxygenase and its therapeutic inhibition in cancer[M]//Galluzzi L(ed).International review of cell and molecular biology.Academic Press,2018:175-203.
• [21]Hooper KM,Yen JH,Kong W,et al.Prostaglandin e₂inhibition of il-27 production in murine dendritic cells:a novel mechanism that involves irf1[J].J Immunology,2017:1-10.
• [22]Herbertz S,Sawyer JS,Stauber AJ,et al.Clinical development of galunisertib(ly2157299 monohydrate),a small molecule inhibitor of transforming growth factor-beta signaling pathway[J].Drug Design Development Therapy,2015,9(4479-4499).
• [23]Verrecchia F,Rédini F.Transforming growth factor-βsignaling plays a pivotal role in the interplay between osteosarcoma cells and their microenvironment[J].Frontiers Oncology,2018,8(133):2-11.
• [24]Johnson LA,Scholler J,Ohkuri T,et al.Rational development and characterization of humanized anti-egfr variant iii chimeric antigen receptor t cells for glioblastoma[J].Sci Translational Med,2015,7(275):222.
• [25]Takahashi Y,Yasui T,Minami K,et al.Radiation enhances the efficacy of antitumor immunotherapy with an immunocomplex of interleukin-2 and its monoclonal antibody[J].Anticancer Res,2017,37(12):6799-6806.
• [26]Dovedi SJ,Adlard AL,Lipowska-Bhalla G,et al.Acquired resistance to fractionated radiotherapy can be overcome by concurrent pd-l1 blockade[J].Cancer Res,2014,74(19):5458-5468.
• [27]Mercatelli D,Bortolotti M,Bazzocchi A,et al.Immunoconjugates for osteosarcoma therapy:preclinical experiences and future perspectives[J].Biomedicines,2018,6(1):1-9.
• [28]Lee JA,Paik EK,Seo J,et al.Radiotherapy and gemcitabinedocetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma[J].Jap J Clin Oncol,2016,46(2):138-143.
• [29]Oushy S,Graner MW.Immunology and immunotherapy in brain tumors-immune failure and potential counteractions[M].2015.
• [30]Sampson JH,Heimberger AB,Archer GE,et al.Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant iii peptide vaccination in patients with newly diagnosed glioblastoma[J].J Clin Oncology,2010,28(31):4722-4729.2018-06-27 2018-08-21